People & Business :: M&A
Merck KGaA to invest in biosimilars, eyes pharma acquisitions
5:34 AM MDT | May 10, 2014 | Natasha Alperowicz
Merck KGaA (Darmstadt, Germany) plans to invest €100 million ($137.6 million) this year in biosimilars, a new business being developed by its Merck Serono unit. In addition, Merck is eyeing pharma acquisition opportunities, particularly in the United States, the world’s largest drugs market, following its recent $2.6-billion acquisition of AZ Electronic Materials. This news emerged on Friday during the company’s annual general meeting (AGM). “As part of ‘Fit for 2018’, the focus of the next two years will be on growth. We are...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee